CAMP4 Therapeutics Corporation Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
CAMP4 Therapeutics Corporation (CAMP) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $9.73 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2025-03-27
- CAMP4 Therapeutics Corporation adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2024 was $9.73M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|
| 2024-12-31 | $9.73M 10-K · filed 2025-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |